CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients Article Swipe
Andreas Gille
,
Denise D’Andrea
,
Michael A. Tortorici
,
Günter Härtel
,
Samuel D. Wright
·
YOU?
·
· 2018
· Open Access
·
· DOI: https://doi.org/10.1161/atvbaha.118.310538
YOU?
·
· 2018
· Open Access
·
· DOI: https://doi.org/10.1161/atvbaha.118.310538
Objective— CSL112 (apolipoprotein A-I [apoA-I; human]) is a novel formulation of apoA-I in development for reduction of early recurrent cardiovascular events after acute myocardial infarction. Cholesterol efflux capacity (CEC) is a marker of high-density lipoprotein (HDL) function that is strongly correlated with incident cardiovascular disease. Impaired CEC has been observed in patients with coronary heart disease. Here, we determined whether infused apoA-I improves CEC when administered to patients with stable atherosclerotic disease versus healthy volunteers. Approach and Results— Measurements of apoA-I, HDL unesterified cholesterol, HDL esterified cholesterol, pre–β1-HDL, and CEC were determined in samples from patients with stable atherosclerotic disease before and after intravenous administration of CSL112. These measures were compared with 2 prior studies in healthy volunteers for differences in CEC at baseline and after CSL112 infusion. Patients with stable atherosclerotic disease exhibited significantly lower ATP-binding cassette transporter 1–mediated CEC at baseline ( P <0.0001) despite slightly higher apoA-I levels when compared with healthy individuals (2 phase 1 studies pooled; P ≤0.05), suggesting impaired HDL function. However, no differences were observed in apoA-I pharmacokinetics or in pre–β1-HDL ( P =0.5) or CEC ( P =0.1) after infusion of CSL112. Similar elevation in CEC was observed in patients with low or high baseline HDL function (based on tertiles of apoA-I–normalized CEC; P =0.1242). These observations were extended and confirmed using cholesterol esterification as an additional measure. Conclusions— CSL112 shows comparable, strong, and immediate effects on CEC despite underlying cardiovascular disease. CSL112 is, therefore, a promising novel therapy for lowering the burden of atherosclerosis and reducing the risk of recurrent cardiovascular events.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1161/atvbaha.118.310538
- https://www.ahajournals.org/doi/pdf/10.1161/ATVBAHA.118.310538
- OA Status
- hybrid
- Cited By
- 64
- References
- 29
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W2785958212
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W2785958212Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1161/atvbaha.118.310538Digital Object Identifier
- Title
-
CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease PatientsWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2018Year of publication
- Publication date
-
2018-02-08Full publication date if available
- Authors
-
Andreas Gille, Denise D’Andrea, Michael A. Tortorici, Günter Härtel, Samuel D. WrightList of authors in order
- Landing page
-
https://doi.org/10.1161/atvbaha.118.310538Publisher landing page
- PDF URL
-
https://www.ahajournals.org/doi/pdf/10.1161/ATVBAHA.118.310538Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
hybridOpen access status per OpenAlex
- OA URL
-
https://www.ahajournals.org/doi/pdf/10.1161/ATVBAHA.118.310538Direct OA link when available
- Concepts
-
Efflux, Cholesterol, Apolipoprotein B, Disease, Internal medicine, Apolipoprotein E, Medicine, Endocrinology, Ldl cholesterol, Vascular disease, Biology, BiochemistryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
64Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 3, 2024: 6, 2023: 8, 2022: 9, 2021: 11Per-year citation counts (last 5 years)
- References (count)
-
29Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W2785958212 |
|---|---|
| doi | https://doi.org/10.1161/atvbaha.118.310538 |
| ids.doi | https://doi.org/10.1161/atvbaha.118.310538 |
| ids.mag | 2785958212 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/29437574 |
| ids.openalex | https://openalex.org/W2785958212 |
| fwci | 10.87927743 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D000293 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Adolescent |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D000328 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Adult |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D000368 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Aged |
| mesh[3].qualifier_ui | Q000097 |
| mesh[3].descriptor_ui | D000924 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | blood |
| mesh[3].descriptor_name | Anticholesteremic Agents |
| mesh[4].qualifier_ui | Q000493 |
| mesh[4].descriptor_ui | D000924 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | pharmacokinetics |
| mesh[4].descriptor_name | Anticholesteremic Agents |
| mesh[5].qualifier_ui | Q000627 |
| mesh[5].descriptor_ui | D000924 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | therapeutic use |
| mesh[5].descriptor_name | Anticholesteremic Agents |
| mesh[6].qualifier_ui | Q000097 |
| mesh[6].descriptor_ui | D016632 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | blood |
| mesh[6].descriptor_name | Apolipoprotein A-I |
| mesh[7].qualifier_ui | Q000493 |
| mesh[7].descriptor_ui | D016632 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | pharmacokinetics |
| mesh[7].descriptor_name | Apolipoprotein A-I |
| mesh[8].qualifier_ui | Q000627 |
| mesh[8].descriptor_ui | D016632 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | therapeutic use |
| mesh[8].descriptor_name | Apolipoprotein A-I |
| mesh[9].qualifier_ui | Q000097 |
| mesh[9].descriptor_ui | D050197 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | blood |
| mesh[9].descriptor_name | Atherosclerosis |
| mesh[10].qualifier_ui | Q000175 |
| mesh[10].descriptor_ui | D050197 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | diagnosis |
| mesh[10].descriptor_name | Atherosclerosis |
| mesh[11].qualifier_ui | Q000188 |
| mesh[11].descriptor_ui | D050197 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | drug therapy |
| mesh[11].descriptor_name | Atherosclerosis |
| mesh[12].qualifier_ui | Q000097 |
| mesh[12].descriptor_ui | D015415 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | blood |
| mesh[12].descriptor_name | Biomarkers |
| mesh[13].qualifier_ui | Q000097 |
| mesh[13].descriptor_ui | D002784 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | blood |
| mesh[13].descriptor_name | Cholesterol |
| mesh[14].qualifier_ui | Q000097 |
| mesh[14].descriptor_ui | D008076 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | blood |
| mesh[14].descriptor_name | Cholesterol, HDL |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D005260 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Female |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D064368 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Healthy Volunteers |
| mesh[17].qualifier_ui | Q000097 |
| mesh[17].descriptor_ui | D053442 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | blood |
| mesh[17].descriptor_name | High-Density Lipoproteins, Pre-beta |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D006801 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Humans |
| mesh[19].qualifier_ui | Q000187 |
| mesh[19].descriptor_ui | D050356 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | drug effects |
| mesh[19].descriptor_name | Lipid Metabolism |
| mesh[20].qualifier_ui | Q000097 |
| mesh[20].descriptor_ui | D008075 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | blood |
| mesh[20].descriptor_name | Lipoproteins, HDL |
| mesh[21].qualifier_ui | Q000493 |
| mesh[21].descriptor_ui | D008075 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | pharmacokinetics |
| mesh[21].descriptor_name | Lipoproteins, HDL |
| mesh[22].qualifier_ui | Q000627 |
| mesh[22].descriptor_ui | D008075 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | therapeutic use |
| mesh[22].descriptor_name | Lipoproteins, HDL |
| mesh[23].qualifier_ui | |
| mesh[23].descriptor_ui | D008297 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | |
| mesh[23].descriptor_name | Male |
| mesh[24].qualifier_ui | |
| mesh[24].descriptor_ui | D008875 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | |
| mesh[24].descriptor_name | Middle Aged |
| mesh[25].qualifier_ui | |
| mesh[25].descriptor_ui | D011793 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | |
| mesh[25].descriptor_name | Queensland |
| mesh[26].qualifier_ui | |
| mesh[26].descriptor_ui | D013021 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | |
| mesh[26].descriptor_name | South Australia |
| mesh[27].qualifier_ui | |
| mesh[27].descriptor_ui | D016896 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | |
| mesh[27].descriptor_name | Treatment Outcome |
| mesh[28].qualifier_ui | |
| mesh[28].descriptor_ui | D014481 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | |
| mesh[28].descriptor_name | United States |
| mesh[29].qualifier_ui | |
| mesh[29].descriptor_ui | D055815 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | |
| mesh[29].descriptor_name | Young Adult |
| mesh[30].qualifier_ui | |
| mesh[30].descriptor_ui | D000293 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | |
| mesh[30].descriptor_name | Adolescent |
| mesh[31].qualifier_ui | |
| mesh[31].descriptor_ui | D000328 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | |
| mesh[31].descriptor_name | Adult |
| mesh[32].qualifier_ui | |
| mesh[32].descriptor_ui | D000368 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | |
| mesh[32].descriptor_name | Aged |
| mesh[33].qualifier_ui | Q000097 |
| mesh[33].descriptor_ui | D000924 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | blood |
| mesh[33].descriptor_name | Anticholesteremic Agents |
| mesh[34].qualifier_ui | Q000493 |
| mesh[34].descriptor_ui | D000924 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | pharmacokinetics |
| mesh[34].descriptor_name | Anticholesteremic Agents |
| mesh[35].qualifier_ui | Q000627 |
| mesh[35].descriptor_ui | D000924 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | therapeutic use |
| mesh[35].descriptor_name | Anticholesteremic Agents |
| mesh[36].qualifier_ui | Q000097 |
| mesh[36].descriptor_ui | D016632 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | blood |
| mesh[36].descriptor_name | Apolipoprotein A-I |
| mesh[37].qualifier_ui | Q000493 |
| mesh[37].descriptor_ui | D016632 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | pharmacokinetics |
| mesh[37].descriptor_name | Apolipoprotein A-I |
| mesh[38].qualifier_ui | Q000627 |
| mesh[38].descriptor_ui | D016632 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | therapeutic use |
| mesh[38].descriptor_name | Apolipoprotein A-I |
| mesh[39].qualifier_ui | Q000097 |
| mesh[39].descriptor_ui | D050197 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | blood |
| mesh[39].descriptor_name | Atherosclerosis |
| mesh[40].qualifier_ui | Q000175 |
| mesh[40].descriptor_ui | D050197 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | diagnosis |
| mesh[40].descriptor_name | Atherosclerosis |
| mesh[41].qualifier_ui | Q000188 |
| mesh[41].descriptor_ui | D050197 |
| mesh[41].is_major_topic | False |
| mesh[41].qualifier_name | drug therapy |
| mesh[41].descriptor_name | Atherosclerosis |
| mesh[42].qualifier_ui | Q000097 |
| mesh[42].descriptor_ui | D015415 |
| mesh[42].is_major_topic | False |
| mesh[42].qualifier_name | blood |
| mesh[42].descriptor_name | Biomarkers |
| mesh[43].qualifier_ui | Q000097 |
| mesh[43].descriptor_ui | D002784 |
| mesh[43].is_major_topic | False |
| mesh[43].qualifier_name | blood |
| mesh[43].descriptor_name | Cholesterol |
| mesh[44].qualifier_ui | Q000097 |
| mesh[44].descriptor_ui | D008076 |
| mesh[44].is_major_topic | False |
| mesh[44].qualifier_name | blood |
| mesh[44].descriptor_name | Cholesterol, HDL |
| mesh[45].qualifier_ui | |
| mesh[45].descriptor_ui | D005260 |
| mesh[45].is_major_topic | False |
| mesh[45].qualifier_name | |
| mesh[45].descriptor_name | Female |
| mesh[46].qualifier_ui | |
| mesh[46].descriptor_ui | D064368 |
| mesh[46].is_major_topic | False |
| mesh[46].qualifier_name | |
| mesh[46].descriptor_name | Healthy Volunteers |
| mesh[47].qualifier_ui | Q000097 |
| mesh[47].descriptor_ui | D053442 |
| mesh[47].is_major_topic | False |
| mesh[47].qualifier_name | blood |
| mesh[47].descriptor_name | High-Density Lipoproteins, Pre-beta |
| mesh[48].qualifier_ui | |
| mesh[48].descriptor_ui | D006801 |
| mesh[48].is_major_topic | False |
| mesh[48].qualifier_name | |
| mesh[48].descriptor_name | Humans |
| mesh[49].qualifier_ui | Q000187 |
| mesh[49].descriptor_ui | D050356 |
| mesh[49].is_major_topic | False |
| mesh[49].qualifier_name | drug effects |
| mesh[49].descriptor_name | Lipid Metabolism |
| type | article |
| title | CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients |
| biblio.issue | 4 |
| biblio.volume | 38 |
| biblio.last_page | 963 |
| biblio.first_page | 953 |
| topics[0].id | https://openalex.org/T10394 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2746 |
| topics[0].subfield.display_name | Surgery |
| topics[0].display_name | Lipoproteins and Cardiovascular Health |
| topics[1].id | https://openalex.org/T10027 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9994999766349792 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2712 |
| topics[1].subfield.display_name | Endocrinology, Diabetes and Metabolism |
| topics[1].display_name | Diabetes, Cardiovascular Risks, and Lipoproteins |
| topics[2].id | https://openalex.org/T11064 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9926999807357788 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2705 |
| topics[2].subfield.display_name | Cardiology and Cardiovascular Medicine |
| topics[2].display_name | Antiplatelet Therapy and Cardiovascular Diseases |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C200082930 |
| concepts[0].level | 2 |
| concepts[0].score | 0.7404106855392456 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q22327148 |
| concepts[0].display_name | Efflux |
| concepts[1].id | https://openalex.org/C2778163477 |
| concepts[1].level | 2 |
| concepts[1].score | 0.6755645871162415 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q43656 |
| concepts[1].display_name | Cholesterol |
| concepts[2].id | https://openalex.org/C62746215 |
| concepts[2].level | 3 |
| concepts[2].score | 0.6017786860466003 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q14890615 |
| concepts[2].display_name | Apolipoprotein B |
| concepts[3].id | https://openalex.org/C2779134260 |
| concepts[3].level | 2 |
| concepts[3].score | 0.5551968812942505 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q12136 |
| concepts[3].display_name | Disease |
| concepts[4].id | https://openalex.org/C126322002 |
| concepts[4].level | 1 |
| concepts[4].score | 0.5386325120925903 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[4].display_name | Internal medicine |
| concepts[5].id | https://openalex.org/C57089818 |
| concepts[5].level | 3 |
| concepts[5].score | 0.5293415784835815 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q424728 |
| concepts[5].display_name | Apolipoprotein E |
| concepts[6].id | https://openalex.org/C71924100 |
| concepts[6].level | 0 |
| concepts[6].score | 0.5056531429290771 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[6].display_name | Medicine |
| concepts[7].id | https://openalex.org/C134018914 |
| concepts[7].level | 1 |
| concepts[7].score | 0.43830570578575134 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q162606 |
| concepts[7].display_name | Endocrinology |
| concepts[8].id | https://openalex.org/C3019550498 |
| concepts[8].level | 3 |
| concepts[8].score | 0.4327138364315033 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q28749 |
| concepts[8].display_name | Ldl cholesterol |
| concepts[9].id | https://openalex.org/C2777466421 |
| concepts[9].level | 2 |
| concepts[9].score | 0.41926106810569763 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q1266890 |
| concepts[9].display_name | Vascular disease |
| concepts[10].id | https://openalex.org/C86803240 |
| concepts[10].level | 0 |
| concepts[10].score | 0.31894344091415405 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[10].display_name | Biology |
| concepts[11].id | https://openalex.org/C55493867 |
| concepts[11].level | 1 |
| concepts[11].score | 0.17978647351264954 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[11].display_name | Biochemistry |
| keywords[0].id | https://openalex.org/keywords/efflux |
| keywords[0].score | 0.7404106855392456 |
| keywords[0].display_name | Efflux |
| keywords[1].id | https://openalex.org/keywords/cholesterol |
| keywords[1].score | 0.6755645871162415 |
| keywords[1].display_name | Cholesterol |
| keywords[2].id | https://openalex.org/keywords/apolipoprotein-b |
| keywords[2].score | 0.6017786860466003 |
| keywords[2].display_name | Apolipoprotein B |
| keywords[3].id | https://openalex.org/keywords/disease |
| keywords[3].score | 0.5551968812942505 |
| keywords[3].display_name | Disease |
| keywords[4].id | https://openalex.org/keywords/internal-medicine |
| keywords[4].score | 0.5386325120925903 |
| keywords[4].display_name | Internal medicine |
| keywords[5].id | https://openalex.org/keywords/apolipoprotein-e |
| keywords[5].score | 0.5293415784835815 |
| keywords[5].display_name | Apolipoprotein E |
| keywords[6].id | https://openalex.org/keywords/medicine |
| keywords[6].score | 0.5056531429290771 |
| keywords[6].display_name | Medicine |
| keywords[7].id | https://openalex.org/keywords/endocrinology |
| keywords[7].score | 0.43830570578575134 |
| keywords[7].display_name | Endocrinology |
| keywords[8].id | https://openalex.org/keywords/ldl-cholesterol |
| keywords[8].score | 0.4327138364315033 |
| keywords[8].display_name | Ldl cholesterol |
| keywords[9].id | https://openalex.org/keywords/vascular-disease |
| keywords[9].score | 0.41926106810569763 |
| keywords[9].display_name | Vascular disease |
| keywords[10].id | https://openalex.org/keywords/biology |
| keywords[10].score | 0.31894344091415405 |
| keywords[10].display_name | Biology |
| keywords[11].id | https://openalex.org/keywords/biochemistry |
| keywords[11].score | 0.17978647351264954 |
| keywords[11].display_name | Biochemistry |
| language | en |
| locations[0].id | doi:10.1161/atvbaha.118.310538 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S3485792 |
| locations[0].source.issn | 1079-5642, 1524-4636 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 1079-5642 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Arteriosclerosis Thrombosis and Vascular Biology |
| locations[0].source.host_organization | https://openalex.org/P4310315671 |
| locations[0].source.host_organization_name | Lippincott Williams & Wilkins |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310315671, https://openalex.org/P4310318547 |
| locations[0].source.host_organization_lineage_names | Lippincott Williams & Wilkins, Wolters Kluwer |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.ahajournals.org/doi/pdf/10.1161/ATVBAHA.118.310538 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Arteriosclerosis, Thrombosis, and Vascular Biology |
| locations[0].landing_page_url | https://doi.org/10.1161/atvbaha.118.310538 |
| locations[1].id | pmid:29437574 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Arteriosclerosis, thrombosis, and vascular biology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/29437574 |
| locations[2].id | pmh:oai:europepmc.org:4840930 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306400806 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | Europe PMC (PubMed Central) |
| locations[2].source.host_organization | https://openalex.org/I1303153112 |
| locations[2].source.host_organization_name | European Bioinformatics Institute |
| locations[2].source.host_organization_lineage | https://openalex.org/I1303153112 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | |
| locations[2].landing_page_url | http://europepmc.org/pmc/articles/PMC5895137 |
| locations[3].id | pmh:oai:pubmedcentral.nih.gov:5895137 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S2764455111 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | PubMed Central |
| locations[3].source.host_organization | https://openalex.org/I1299303238 |
| locations[3].source.host_organization_name | National Institutes of Health |
| locations[3].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | |
| locations[3].landing_page_url | http://doi.org/10.1161/ATVBAHA.118.310538 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5003187606 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-5235-8897 |
| authorships[0].author.display_name | Andreas Gille |
| authorships[0].countries | AU |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I217937681 |
| authorships[0].affiliations[0].raw_affiliation_string | QIMR Berghofer Medical Research Institute, Brisbane City, Australia (G.H.). |
| authorships[0].affiliations[1].institution_ids | https://openalex.org/I4210153402 |
| authorships[0].affiliations[1].raw_affiliation_string | Andreas Gille From the CSL Limited, Parkville, Australia (A.G.) |
| authorships[0].affiliations[2].institution_ids | https://openalex.org/I217937681, https://openalex.org/I4210153402 |
| authorships[0].affiliations[2].raw_affiliation_string | From the CSL Limited, Parkville, Australia (A.G.); CSL Behring, King of Prussia, PA (D.D., M.A.T., S.D.W.); and QIMR Berghofer Medical Research Institute, Brisbane City, Australia (G.H.). |
| authorships[0].institutions[0].id | https://openalex.org/I4210153402 |
| authorships[0].institutions[0].ror | https://ror.org/044tc0x05 |
| authorships[0].institutions[0].type | company |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210153402 |
| authorships[0].institutions[0].country_code | AU |
| authorships[0].institutions[0].display_name | CSL (Australia) |
| authorships[0].institutions[1].id | https://openalex.org/I217937681 |
| authorships[0].institutions[1].ror | https://ror.org/004y8wk30 |
| authorships[0].institutions[1].type | facility |
| authorships[0].institutions[1].lineage | https://openalex.org/I217937681 |
| authorships[0].institutions[1].country_code | AU |
| authorships[0].institutions[1].display_name | QIMR Berghofer Medical Research Institute |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Andreas Gille |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Andreas Gille From the CSL Limited, Parkville, Australia (A.G.), From the CSL Limited, Parkville, Australia (A.G.); CSL Behring, King of Prussia, PA (D.D., M.A.T., S.D.W.); and QIMR Berghofer Medical Research Institute, Brisbane City, Australia (G.H.)., QIMR Berghofer Medical Research Institute, Brisbane City, Australia (G.H.). |
| authorships[1].author.id | https://openalex.org/A5083196007 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Denise D’Andrea |
| authorships[1].countries | AU |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I217937681, https://openalex.org/I4210153402 |
| authorships[1].affiliations[0].raw_affiliation_string | From the CSL Limited, Parkville, Australia (A.G.); CSL Behring, King of Prussia, PA (D.D., M.A.T., S.D.W.); and QIMR Berghofer Medical Research Institute, Brisbane City, Australia (G.H.). |
| authorships[1].affiliations[1].institution_ids | https://openalex.org/I217937681 |
| authorships[1].affiliations[1].raw_affiliation_string | QIMR Berghofer Medical Research Institute, Brisbane City, Australia (G.H.). |
| authorships[1].affiliations[2].institution_ids | https://openalex.org/I4210153402 |
| authorships[1].affiliations[2].raw_affiliation_string | Denise D'Andrea From the CSL Limited, Parkville, Australia (A.G.) |
| authorships[1].institutions[0].id | https://openalex.org/I4210153402 |
| authorships[1].institutions[0].ror | https://ror.org/044tc0x05 |
| authorships[1].institutions[0].type | company |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210153402 |
| authorships[1].institutions[0].country_code | AU |
| authorships[1].institutions[0].display_name | CSL (Australia) |
| authorships[1].institutions[1].id | https://openalex.org/I217937681 |
| authorships[1].institutions[1].ror | https://ror.org/004y8wk30 |
| authorships[1].institutions[1].type | facility |
| authorships[1].institutions[1].lineage | https://openalex.org/I217937681 |
| authorships[1].institutions[1].country_code | AU |
| authorships[1].institutions[1].display_name | QIMR Berghofer Medical Research Institute |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Denise D’Andrea |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Denise D'Andrea From the CSL Limited, Parkville, Australia (A.G.), From the CSL Limited, Parkville, Australia (A.G.); CSL Behring, King of Prussia, PA (D.D., M.A.T., S.D.W.); and QIMR Berghofer Medical Research Institute, Brisbane City, Australia (G.H.)., QIMR Berghofer Medical Research Institute, Brisbane City, Australia (G.H.). |
| authorships[2].author.id | https://openalex.org/A5013142762 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-2822-5805 |
| authorships[2].author.display_name | Michael A. Tortorici |
| authorships[2].countries | AU |
| authorships[2].affiliations[0].raw_affiliation_string | Michael A. Tortorici From the CSL Limited, Parkville, Australia (A.G.) |
| authorships[2].affiliations[1].institution_ids | https://openalex.org/I217937681 |
| authorships[2].affiliations[1].raw_affiliation_string | QIMR Berghofer Medical Research Institute, Brisbane City, Australia (G.H.). |
| authorships[2].affiliations[2].institution_ids | https://openalex.org/I217937681, https://openalex.org/I4210153402 |
| authorships[2].affiliations[2].raw_affiliation_string | From the CSL Limited, Parkville, Australia (A.G.); CSL Behring, King of Prussia, PA (D.D., M.A.T., S.D.W.); and QIMR Berghofer Medical Research Institute, Brisbane City, Australia (G.H.). |
| authorships[2].institutions[0].id | https://openalex.org/I4210153402 |
| authorships[2].institutions[0].ror | https://ror.org/044tc0x05 |
| authorships[2].institutions[0].type | company |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210153402 |
| authorships[2].institutions[0].country_code | AU |
| authorships[2].institutions[0].display_name | CSL (Australia) |
| authorships[2].institutions[1].id | https://openalex.org/I217937681 |
| authorships[2].institutions[1].ror | https://ror.org/004y8wk30 |
| authorships[2].institutions[1].type | facility |
| authorships[2].institutions[1].lineage | https://openalex.org/I217937681 |
| authorships[2].institutions[1].country_code | AU |
| authorships[2].institutions[1].display_name | QIMR Berghofer Medical Research Institute |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Michael A. Tortorici |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | From the CSL Limited, Parkville, Australia (A.G.); CSL Behring, King of Prussia, PA (D.D., M.A.T., S.D.W.); and QIMR Berghofer Medical Research Institute, Brisbane City, Australia (G.H.)., Michael A. Tortorici From the CSL Limited, Parkville, Australia (A.G.), QIMR Berghofer Medical Research Institute, Brisbane City, Australia (G.H.). |
| authorships[3].author.id | https://openalex.org/A5069155052 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-5454-6450 |
| authorships[3].author.display_name | Günter Härtel |
| authorships[3].countries | AU |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I217937681, https://openalex.org/I4210153402 |
| authorships[3].affiliations[0].raw_affiliation_string | From the CSL Limited, Parkville, Australia (A.G.); CSL Behring, King of Prussia, PA (D.D., M.A.T., S.D.W.); and QIMR Berghofer Medical Research Institute, Brisbane City, Australia (G.H.). |
| authorships[3].affiliations[1].institution_ids | https://openalex.org/I4210153402 |
| authorships[3].affiliations[1].raw_affiliation_string | Gunter Hartel From the CSL Limited, Parkville, Australia (A.G.) |
| authorships[3].affiliations[2].institution_ids | https://openalex.org/I217937681 |
| authorships[3].affiliations[2].raw_affiliation_string | QIMR Berghofer Medical Research Institute, Brisbane City, Australia (G.H.). |
| authorships[3].institutions[0].id | https://openalex.org/I4210153402 |
| authorships[3].institutions[0].ror | https://ror.org/044tc0x05 |
| authorships[3].institutions[0].type | company |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210153402 |
| authorships[3].institutions[0].country_code | AU |
| authorships[3].institutions[0].display_name | CSL (Australia) |
| authorships[3].institutions[1].id | https://openalex.org/I217937681 |
| authorships[3].institutions[1].ror | https://ror.org/004y8wk30 |
| authorships[3].institutions[1].type | facility |
| authorships[3].institutions[1].lineage | https://openalex.org/I217937681 |
| authorships[3].institutions[1].country_code | AU |
| authorships[3].institutions[1].display_name | QIMR Berghofer Medical Research Institute |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Gunter Hartel |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | From the CSL Limited, Parkville, Australia (A.G.); CSL Behring, King of Prussia, PA (D.D., M.A.T., S.D.W.); and QIMR Berghofer Medical Research Institute, Brisbane City, Australia (G.H.)., Gunter Hartel From the CSL Limited, Parkville, Australia (A.G.), QIMR Berghofer Medical Research Institute, Brisbane City, Australia (G.H.). |
| authorships[4].author.id | https://openalex.org/A5076210539 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-5583-0595 |
| authorships[4].author.display_name | Samuel D. Wright |
| authorships[4].countries | AU |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I217937681, https://openalex.org/I4210153402 |
| authorships[4].affiliations[0].raw_affiliation_string | From the CSL Limited, Parkville, Australia (A.G.); CSL Behring, King of Prussia, PA (D.D., M.A.T., S.D.W.); and QIMR Berghofer Medical Research Institute, Brisbane City, Australia (G.H.). |
| authorships[4].affiliations[1].institution_ids | https://openalex.org/I217937681 |
| authorships[4].affiliations[1].raw_affiliation_string | QIMR Berghofer Medical Research Institute, Brisbane City, Australia (G.H.). |
| authorships[4].affiliations[2].institution_ids | https://openalex.org/I4210153402 |
| authorships[4].affiliations[2].raw_affiliation_string | Samuel D. Wright From the CSL Limited, Parkville, Australia (A.G.) |
| authorships[4].institutions[0].id | https://openalex.org/I4210153402 |
| authorships[4].institutions[0].ror | https://ror.org/044tc0x05 |
| authorships[4].institutions[0].type | company |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210153402 |
| authorships[4].institutions[0].country_code | AU |
| authorships[4].institutions[0].display_name | CSL (Australia) |
| authorships[4].institutions[1].id | https://openalex.org/I217937681 |
| authorships[4].institutions[1].ror | https://ror.org/004y8wk30 |
| authorships[4].institutions[1].type | facility |
| authorships[4].institutions[1].lineage | https://openalex.org/I217937681 |
| authorships[4].institutions[1].country_code | AU |
| authorships[4].institutions[1].display_name | QIMR Berghofer Medical Research Institute |
| authorships[4].author_position | last |
| authorships[4].raw_author_name | Samuel D. Wright |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | From the CSL Limited, Parkville, Australia (A.G.); CSL Behring, King of Prussia, PA (D.D., M.A.T., S.D.W.); and QIMR Berghofer Medical Research Institute, Brisbane City, Australia (G.H.)., QIMR Berghofer Medical Research Institute, Brisbane City, Australia (G.H.)., Samuel D. Wright From the CSL Limited, Parkville, Australia (A.G.) |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.ahajournals.org/doi/pdf/10.1161/ATVBAHA.118.310538 |
| open_access.oa_status | hybrid |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10394 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2746 |
| primary_topic.subfield.display_name | Surgery |
| primary_topic.display_name | Lipoproteins and Cardiovascular Health |
| related_works | https://openalex.org/W4294636674, https://openalex.org/W2501597952, https://openalex.org/W1971121351, https://openalex.org/W2278849149, https://openalex.org/W2901573124, https://openalex.org/W2602160643, https://openalex.org/W2418191988, https://openalex.org/W1995547459, https://openalex.org/W3029836679, https://openalex.org/W4292260758 |
| cited_by_count | 64 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 3 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 6 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 8 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 9 |
| counts_by_year[4].year | 2021 |
| counts_by_year[4].cited_by_count | 11 |
| counts_by_year[5].year | 2020 |
| counts_by_year[5].cited_by_count | 9 |
| counts_by_year[6].year | 2019 |
| counts_by_year[6].cited_by_count | 12 |
| counts_by_year[7].year | 2018 |
| counts_by_year[7].cited_by_count | 6 |
| locations_count | 4 |
| best_oa_location.id | doi:10.1161/atvbaha.118.310538 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S3485792 |
| best_oa_location.source.issn | 1079-5642, 1524-4636 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 1079-5642 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Arteriosclerosis Thrombosis and Vascular Biology |
| best_oa_location.source.host_organization | https://openalex.org/P4310315671 |
| best_oa_location.source.host_organization_name | Lippincott Williams & Wilkins |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310315671, https://openalex.org/P4310318547 |
| best_oa_location.source.host_organization_lineage_names | Lippincott Williams & Wilkins, Wolters Kluwer |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.ahajournals.org/doi/pdf/10.1161/ATVBAHA.118.310538 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Arteriosclerosis, Thrombosis, and Vascular Biology |
| best_oa_location.landing_page_url | https://doi.org/10.1161/atvbaha.118.310538 |
| primary_location.id | doi:10.1161/atvbaha.118.310538 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S3485792 |
| primary_location.source.issn | 1079-5642, 1524-4636 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 1079-5642 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Arteriosclerosis Thrombosis and Vascular Biology |
| primary_location.source.host_organization | https://openalex.org/P4310315671 |
| primary_location.source.host_organization_name | Lippincott Williams & Wilkins |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310315671, https://openalex.org/P4310318547 |
| primary_location.source.host_organization_lineage_names | Lippincott Williams & Wilkins, Wolters Kluwer |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.ahajournals.org/doi/pdf/10.1161/ATVBAHA.118.310538 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Arteriosclerosis, Thrombosis, and Vascular Biology |
| primary_location.landing_page_url | https://doi.org/10.1161/atvbaha.118.310538 |
| publication_date | 2018-02-08 |
| publication_year | 2018 |
| referenced_works | https://openalex.org/W2140501627, https://openalex.org/W2131110587, https://openalex.org/W2055823448, https://openalex.org/W2109429564, https://openalex.org/W2098290541, https://openalex.org/W2398353187, https://openalex.org/W2416480748, https://openalex.org/W2097104644, https://openalex.org/W2008062676, https://openalex.org/W2549082007, https://openalex.org/W2154023449, https://openalex.org/W2130702577, https://openalex.org/W2175680864, https://openalex.org/W2531332275, https://openalex.org/W2065296729, https://openalex.org/W2260995852, https://openalex.org/W2194982046, https://openalex.org/W1653290827, https://openalex.org/W1986524045, https://openalex.org/W2067514230, https://openalex.org/W2498364729, https://openalex.org/W2102227401, https://openalex.org/W2160623724, https://openalex.org/W2118754602, https://openalex.org/W2183216836, https://openalex.org/W1690616900, https://openalex.org/W2888852359, https://openalex.org/W2224539324, https://openalex.org/W3020620046 |
| referenced_works_count | 29 |
| abstract_inverted_index.( | 143, 178, 183 |
| abstract_inverted_index.1 | 158 |
| abstract_inverted_index.2 | 112 |
| abstract_inverted_index.P | 144, 161, 179, 184, 211 |
| abstract_inverted_index.a | 7, 30, 243 |
| abstract_inverted_index.(2 | 156 |
| abstract_inverted_index.an | 223 |
| abstract_inverted_index.as | 222 |
| abstract_inverted_index.at | 122, 141 |
| abstract_inverted_index.in | 12, 50, 92, 115, 120, 172, 176, 192, 196 |
| abstract_inverted_index.is | 6, 29, 38 |
| abstract_inverted_index.no | 168 |
| abstract_inverted_index.of | 10, 16, 32, 79, 105, 188, 208, 251, 257 |
| abstract_inverted_index.on | 206, 234 |
| abstract_inverted_index.or | 175, 181, 200 |
| abstract_inverted_index.to | 66 |
| abstract_inverted_index.we | 57 |
| abstract_inverted_index.A-I | 3 |
| abstract_inverted_index.CEC | 46, 63, 89, 121, 140, 182, 193, 235 |
| abstract_inverted_index.HDL | 81, 84, 165, 203 |
| abstract_inverted_index.and | 76, 88, 101, 124, 217, 231, 253 |
| abstract_inverted_index.for | 14, 118, 247 |
| abstract_inverted_index.has | 47 |
| abstract_inverted_index.is, | 241 |
| abstract_inverted_index.low | 199 |
| abstract_inverted_index.the | 249, 255 |
| abstract_inverted_index.was | 194 |
| abstract_inverted_index.CEC; | 210 |
| abstract_inverted_index.been | 48 |
| abstract_inverted_index.from | 94 |
| abstract_inverted_index.high | 201 |
| abstract_inverted_index.risk | 256 |
| abstract_inverted_index.that | 37 |
| abstract_inverted_index.were | 90, 109, 170, 215 |
| abstract_inverted_index.when | 64, 151 |
| abstract_inverted_index.with | 41, 52, 68, 96, 111, 129, 153, 198 |
| abstract_inverted_index.(CEC) | 28 |
| abstract_inverted_index.(HDL) | 35 |
| abstract_inverted_index.=0.1) | 185 |
| abstract_inverted_index.=0.5) | 180 |
| abstract_inverted_index.Here, | 56 |
| abstract_inverted_index.These | 107, 213 |
| abstract_inverted_index.acute | 22 |
| abstract_inverted_index.after | 21, 102, 125, 186 |
| abstract_inverted_index.early | 17 |
| abstract_inverted_index.heart | 54 |
| abstract_inverted_index.lower | 135 |
| abstract_inverted_index.novel | 8, 245 |
| abstract_inverted_index.phase | 157 |
| abstract_inverted_index.prior | 113 |
| abstract_inverted_index.shows | 228 |
| abstract_inverted_index.using | 219 |
| abstract_inverted_index.(based | 205 |
| abstract_inverted_index.CSL112 | 1, 126, 227, 240 |
| abstract_inverted_index.apoA-I | 11, 61, 149, 173 |
| abstract_inverted_index.before | 100 |
| abstract_inverted_index.burden | 250 |
| abstract_inverted_index.efflux | 26 |
| abstract_inverted_index.events | 20 |
| abstract_inverted_index.higher | 148 |
| abstract_inverted_index.levels | 150 |
| abstract_inverted_index.marker | 31 |
| abstract_inverted_index.stable | 69, 97, 130 |
| abstract_inverted_index.versus | 72 |
| abstract_inverted_index.CSL112. | 106, 189 |
| abstract_inverted_index.Similar | 190 |
| abstract_inverted_index.apoA-I, | 80 |
| abstract_inverted_index.despite | 146, 236 |
| abstract_inverted_index.disease | 71, 99, 132 |
| abstract_inverted_index.effects | 233 |
| abstract_inverted_index.events. | 260 |
| abstract_inverted_index.healthy | 73, 116, 154 |
| abstract_inverted_index.human]) | 5 |
| abstract_inverted_index.infused | 60 |
| abstract_inverted_index.pooled; | 160 |
| abstract_inverted_index.samples | 93 |
| abstract_inverted_index.strong, | 230 |
| abstract_inverted_index.studies | 114, 159 |
| abstract_inverted_index.therapy | 246 |
| abstract_inverted_index.whether | 59 |
| abstract_inverted_index.Approach | 75 |
| abstract_inverted_index.However, | 167 |
| abstract_inverted_index.Impaired | 45 |
| abstract_inverted_index.Patients | 128 |
| abstract_inverted_index.[apoA-I; | 4 |
| abstract_inverted_index.baseline | 123, 142, 202 |
| abstract_inverted_index.capacity | 27 |
| abstract_inverted_index.cassette | 137 |
| abstract_inverted_index.compared | 110, 152 |
| abstract_inverted_index.coronary | 53 |
| abstract_inverted_index.disease. | 44, 55, 239 |
| abstract_inverted_index.extended | 216 |
| abstract_inverted_index.function | 36, 204 |
| abstract_inverted_index.impaired | 164 |
| abstract_inverted_index.improves | 62 |
| abstract_inverted_index.incident | 42 |
| abstract_inverted_index.infusion | 187 |
| abstract_inverted_index.lowering | 248 |
| abstract_inverted_index.measure. | 225 |
| abstract_inverted_index.measures | 108 |
| abstract_inverted_index.observed | 49, 171, 195 |
| abstract_inverted_index.patients | 51, 67, 95, 197 |
| abstract_inverted_index.reducing | 254 |
| abstract_inverted_index.slightly | 147 |
| abstract_inverted_index.strongly | 39 |
| abstract_inverted_index.tertiles | 207 |
| abstract_inverted_index.=0.1242). | 212 |
| abstract_inverted_index.confirmed | 218 |
| abstract_inverted_index.elevation | 191 |
| abstract_inverted_index.exhibited | 133 |
| abstract_inverted_index.function. | 166 |
| abstract_inverted_index.immediate | 232 |
| abstract_inverted_index.infusion. | 127 |
| abstract_inverted_index.promising | 244 |
| abstract_inverted_index.recurrent | 18, 258 |
| abstract_inverted_index.reduction | 15 |
| abstract_inverted_index.≤0.05), | 162 |
| abstract_inverted_index.Results— | 77 |
| abstract_inverted_index.additional | 224 |
| abstract_inverted_index.correlated | 40 |
| abstract_inverted_index.determined | 58, 91 |
| abstract_inverted_index.esterified | 85 |
| abstract_inverted_index.myocardial | 23 |
| abstract_inverted_index.suggesting | 163 |
| abstract_inverted_index.therefore, | 242 |
| abstract_inverted_index.underlying | 237 |
| abstract_inverted_index.volunteers | 117 |
| abstract_inverted_index.<0.0001) | 145 |
| abstract_inverted_index.ATP-binding | 136 |
| abstract_inverted_index.Cholesterol | 25 |
| abstract_inverted_index.cholesterol | 220 |
| abstract_inverted_index.comparable, | 229 |
| abstract_inverted_index.development | 13 |
| abstract_inverted_index.differences | 119, 169 |
| abstract_inverted_index.formulation | 9 |
| abstract_inverted_index.individuals | 155 |
| abstract_inverted_index.infarction. | 24 |
| abstract_inverted_index.intravenous | 103 |
| abstract_inverted_index.lipoprotein | 34 |
| abstract_inverted_index.transporter | 138 |
| abstract_inverted_index.volunteers. | 74 |
| abstract_inverted_index.1–mediated | 139 |
| abstract_inverted_index.Measurements | 78 |
| abstract_inverted_index.Objective— | 0 |
| abstract_inverted_index.administered | 65 |
| abstract_inverted_index.cholesterol, | 83, 86 |
| abstract_inverted_index.high-density | 33 |
| abstract_inverted_index.observations | 214 |
| abstract_inverted_index.unesterified | 82 |
| abstract_inverted_index.pre–β1-HDL | 177 |
| abstract_inverted_index.significantly | 134 |
| abstract_inverted_index.Conclusions— | 226 |
| abstract_inverted_index.administration | 104 |
| abstract_inverted_index.cardiovascular | 19, 43, 238, 259 |
| abstract_inverted_index.esterification | 221 |
| abstract_inverted_index.pre–β1-HDL, | 87 |
| abstract_inverted_index.(apolipoprotein | 2 |
| abstract_inverted_index.atherosclerosis | 252 |
| abstract_inverted_index.atherosclerotic | 70, 98, 131 |
| abstract_inverted_index.pharmacokinetics | 174 |
| abstract_inverted_index.apoA-I–normalized | 209 |
| cited_by_percentile_year.max | 99 |
| cited_by_percentile_year.min | 97 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 5 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8399999737739563 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.98412698 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |